Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/13588
Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study
StatisticsItem usage statistics
MetadataShow Dublin Core item record
AuthorTorregrosa, Josep V.; Morales, Enrique; Diaz, Juan M.; Crespo, Josep; Bravo, Juan; Gomez, Gonzalo; Gentil, Miguel A.; Rodriguez-Benot, Alberto; Rodriguez-Garcia, Minerva; Lopez-Jimenez, Veronica; Gutierrez-Dalmau, Alex; Jimeno, Luisa; Jose Perez-Saez, M.; Romero, Rafael; Gomez-Alamillo, Carlos; Grp Estudio CINAREN
Document typeresearch article
CitationTorregrosa JV, Morales E, Diaz JM, Crespo J, Bravo J, Gomez G, et al. Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study. Nefrologia. 2014;34(1):62-8.
Background: The effect of cinacalcet in patients with persistent secondary hyperparathyroidism (SHPT) after kidney transplantation (KT) has mainly been reported in patients with secondary hypercalcaemia. Objectives: Our objective was to assess the long-term effect of cinacalcet on patients with a KT and normocalcaemic SHPT. Methods: A one-year multicentre, observational, retrospective study that included kidney recipients with SHPT (intact parathyroid hormone [iPTH] > 120pg/ml) and calcium levels within the normal range (8.4-10.2mg/dl). Patients began treatment with cinacalcet in clinical practice. Results: 32 patients with a mean age (standard deviation [SD] of 54 (11) years, 56% male, were included in the study. Treatment with cinacalcet began a median of 16 months after KT (median dose of 30mg/day). Levels of iPTH decreased from a median (P25, P75) of 364 (220, 531) pg/ml at the start of the study to 187 (98, 320) after 6 months (48.6% reduction, P=.001) and to 145 (91, 195) after 12 months (60.2% reduction, P=.001), without there being changes in calcium and phosphorus levels (P=.214 and P=.216, respectively). No changes were observed in kidney function or anti-calcineuric drug levels. 3.1% of patients discontinued cinacalcet due to intolerance and 6.2% due to a lack of efficacy. Conclusions: In patients with normocalcaemic SHPT after KT cinacalcet improves the control of serum PTH values without causing changes to calcaemia, phosphataemia or kidney function. Cinacalcet showed good tolerability.
DeCSEstudios de Seguimiento
Persona de Mediana Edad
Factores de Tiempo
Trasplante de Riñón